Our study shows that using a pre-hospital blood test to guide tPA may be a cost-effective strategy in a hypothetical cohort of patients with suspected moderate to severe stroke (NIHSS 4-22) within 4.5 h after symptom onset from the Spanish Health System perspective. The gene discussed is PLAT; the disease is stroke disorder.